http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2767652-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 |
filingDate | 2018-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb5d84d0b48d215a4210eea623424d22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c68d0146be9409678c4ff300f409d31f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258c438559aebe1dc6668c194597daf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aee6a8f91d083e1a51d2b0c8e62219ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_843448304a5e8e2959c1949b3e0d0cfc |
publicationDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2767652-C2 |
titleOfInvention | New compounds |
abstract | FIELD: pharmaceutics. n SUBSTANCE: invention relates to organic compounds. Disclosed is a compound or a pharmaceutically acceptable salt thereof, selected from the following compounds: 4,4,4-trifluoro-1-[4-fluoro-4-(3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(5-fluoro-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-fluoro-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[6-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[4-(trifluoromethyl)-2-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[5-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[6-(trifluoromethyl)-2-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-fluoro-2-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(6-methoxy-3-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-[2-(trifluoromethyl)-3-pyridyl]-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-[4-(5-methoxy-3-pyridyl)-1-piperidyl] butan-1-one; 1-[4-(3,5-difluoro-2-pyridyl)-1-piperidyl]-4,4,4-trifluoro-butan-1-one; 1-[4-(2,6-difluoro-3-pyridyl)-1-piperidyl]-4,4,4-trifluoro-butan-1-one; 4,4,4-trifluoro-1-[4-(5-fluoro-2-pyridyl)-1-piperidyl]butan-1-one; 4,4,4-trifluoro-1-(4-(2-(trifluoromethyl)pyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(2-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(5-(trifluoromethyl)pyrazin-2-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-(2-methylpyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(5,6-difluoropyridin-3-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-(6-(trifluoromethyl)pyrazin-2-yl)piperidin-1-yl)butan-1-one; 1-(4-(2-chloropyridin-4-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-(3-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(6-chloropyridin-2-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)-4-fluoropiperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 1-(4-(5-chloropyridin-3-yl)piperidin-1-yl)-5,5,5-trifluoropentan-1-one; 1-(4-(6-chloropyrazin-2-yl)piperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(pyridin-2-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(5-(trifluoromethyl)pyridin-3-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(2-(trifluoromethyl)pyridin-4-yl)piperidin-1-yl)butan-1-one; 1-(4-(6-chloropyrazin-2-yl)-4-fluoropiperidin-1-yl)-4,4,4-trifluorobutan-1-one; 4,4,4-trifluoro-1-(4-fluoro-4-(2-fluoropyridin-4-yl)piperidin-1-yl)butan-1-one; 4,4,4-trifluoro-1- [4-fluoro-4- [4-(trifluoromethyl)-2-pyridyl]-1-piperidyl] butan-1-one; 1-(3-(5-chloropyridin-3-yl)pyrrolidin-1-yl)-4,4,4-trifluorobutan-1-one; and 1-[4-(2-chloro-4-pyridyl)-4-fluoro-1-piperidyl]-4,4,4-trifluoro-butan-1-one. Also disclosed is a pharmaceutical composition and a combination containing said compound, use and methods of treating mycobacterial infection and disease caused by Mycobacterium tuberculosis infection. n EFFECT: development of new compounds applicable in treating mycobacterial infections and diseases caused by mycobacteria. n 14 cl, 14 tbl, 41 ex |
priorityDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 488.